Insulet Q2 preliminary revenue $488M (+23% YoY), raises FY Omnipod guidance to 18-21%

INSULET CORP

2024-Q2 EPS reported $3.32 revenue$930,200,000

Q2 revenue $488M, up 23% YoY, exceeding guidance of 15-18% constant currency growth.
Total Omnipod revenue $480M (+26%): US $352M (+27%), International $128M (+23%, +24% CC).
Drug Delivery revenue $8M.
Raises FY 2024 total Omnipod revenue growth outlook to 18-21% from prior 15-19%.
Full Q2 results and call scheduled for August 8, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.